CMC Biologics, a worldwide leader in commercial and clinical development and contract manufacturer of therapeutic proteins, recently announced a new agreement with PATH Malaria Vaccine Initiative (MVI) to create and produce malaria-specific monoclonal antibodies against malaria infections.
According to the agreement, CMC Biologics will create a CHEF1 production ell line and a process to produce MVI’s monoclonal antibody. The antibody is designed to specifically target circumsporozoite protein (CSP), which was created by MVI to protect people from P. falciparum infections.
"By utilizing CMC Biologics' 2.012 accelerated monoclonal antibody development solution, we will help MVI achieve its mission to accelerate the development of promising malaria vaccines, for much needed use in the developing world," CMC Biologics Global Chief Operations Officer Gustavo Mahler said. "We will deliver cGMP material for MVI's preclinical and phase I/II clinical studies in a remarkable 12 months – the fastest development timeline in the industry from DNA to delivery."
MVI Director Ashley Birkett said they chose to partner with CMC Biologics for their sophisticated technical capabilities, successful track record in the industry, and speed of antibody development and production.
"Assuming this initial study is successful, we will evaluate other antibodies targeting novel vaccine targets for their capacity to protect humans from infection and therefore inform future vaccine development efforts," she said.